EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2. EpiVax will be carrying out the vaccine epitope selection portion of the collaboration using their comprehensive in silico vaccine design toolkit "iVAX" ( https://c212.net/c/link/?t=0&l=en&o=3692683-1&h=2887996362&u=https%3A%2F%2Fepivax.com%2Fimmunogenicity-assessment%2Fivax-web-based-vaccine-design&a=their+comprehensive+in+silico+vaccine+design+toolkit+%22iVAX%22 ). Logo - https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg This program is funded under CEPI's 2021 call for proposals ( https://c212.net/c/link/?t=0&l=en&o=3692683-1&h=1939935105&u=https%3A%2F%2Fcepi.net%2Fnews_cepi%2Fcepi-launches-funding-call-to-advance-development-of-broadly-protective-coronavirus-vaccines%2F&a=CEPI%27s+2021+call+for+proposals ) to accelerate the development of broadly protective coronavirus vaccines, which will provide up to US$200 million for such projects. Intravacc was awarded $4.8 million to advance their subunit vaccine candidate "Avacc 101" ( https://c212.net/c/link/?t=0&l=en&o=3692683-1&h=1203321623&u=https%3A%2F%2Fcepi.net%2Fnews_cepi%2Fcepi-partners-with-intravacc-to-develop-an-intranasal-broadly-protective-betacoronavirus-vaccine%2F&a=Intravacc+was+awarded+%244.8+million+to+advance+their+subunit+vaccine+candidate+%22Avacc+101 ), which is designed for intranasal delivery to provide protective immunity for multiple betacoronaviruses including SARS-CoV-1, SARS-CoV-2, and MERS-CoV. Avacc 101 uses Intravacc's Outer Membrane Vesicle (OMV) technology ( https://c212.net/c/link/?t=0&l=en&o=3692683-1&h=1303454865&u=https%3A%2F%2Fwww.intravacc.nl%2Fplatforms%2Fouter-membrane-vesicles-platform%2F&a=Intravacc%27s+Outer+Membrane+Vesicle+(OMV)+technology ) to deliver vaccine payloads for an effective immune response. As a subgrantee on the project, EpiVax will identify cross-reactive beta-coronavirus T cell epitopes for broad coverage of COVID-19, MERS and SARS Class 1 and Class 2 HLA-restricted epitopes, using the iVAX in silico vaccine design toolkit ( https://c212.net/c/link/?t=0&l=en&o=3692683-1&h=3280241035&u=https%3A%2F%2Fepivax.com%2Fimmunogenicity-assessment%2Fivax-web-based-vaccine-design&a=iVAX+in+silico+vaccine+design+toolkit ). In addition to vaccine epitope selection, EpiVax will also develop multiple designs, and will validate these in silico constructs in vivo with HLA-transgenic mice. According to EpiVax CEO/CSO Dr. Annie De Groot, "We sincerely appreciate the opportunity to apply our advanced vaccine design tools to a problem of global significance.". About EpiVax: EpiVax is a biotechnology company with expertise in T cell epitope prediction, immune modulation, and rapid vaccine design. EpiVax's immunogenicity screening toolkits for therapeutics and vaccines, ISPRI and iVAX, are employed in advancing the research of a global roster of companies. For more information, visit www.epivax.com. About Intravacc: Intravacc is a leading global contract development and manufacturing organization (CDMO) of innovative vaccines against infectious diseases. Intravacc has transferred its technology related to polio vaccines, measles vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world. Intravacc offers a wide range of expertise to develop vaccine from concept to Phase I/II clinical studies for academic, industry and philanthropic partners. For more information, visit www.intravacc.nl. Press Contact: Katie Porter, Associate Director, Business Development & Marketing EpiVax kporter@epivax.com Source: EpiVax Inc.